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Abstract 
The initial metabolism of fructose is thought to primarily take place in the liver. Using 
stable isotope labelling and tissue/arterio-venous sampling, Jang et al. demonstrate 
that in mice, the small intestine is the primary site of fructose metabolism, raising 
important questions about fructose handling in humans. 
 
Main body 
Global health guidelines are calling for reductions in consumption of dietary sugars 
due to concerns over their potential role in disease. Prominent dietary sugars include 
sucrose, lactose and their constituent monomers, glucose, fructose and galactose. Of 
these, fructose has been identified as a primary candidate responsible for poor health 
outcomes resulting from high sugar intake. A high fructose intake can stimulate 
endogenous glucose production and lipid synthesis which can increase fasted and 
postprandial glucose and triglyceride concentrations. While the primary site of oral 
fructose metabolism was thought to be the liver, Jang et al. employ a sophisticated 
combination of stable isotopes, isotopomers and tissue/arterio-venous sampling to 
reveal that most ingested fructose is in fact, initially metabolised by the small intestine 
in mice (Jang et al., 2018).  
 In humans, plasma fructose concentrations remain relatively low (<0.5 mmol·L-
1), even when ingesting large fructose doses. Since peripheral tissues such as skeletal 
muscle have a low capacity for fructose metabolism, fructose is first heavily 
metabolised prior to entering the systemic circulation. The liver is one such organ with 
capacity for this initial phosphorylation due to a high abundance of ketohexokinase 
(Gonzalez et al., 2017). Direct assessment of hepatic and intestinal metabolism in vivo 
is notoriously difficult due to (in)accessibility of these organs, and current knowledge 
in this area could therefore be considered a black box. However, these new data from 
Jang et al. (2018) demonstrate that ~90% of fructose phosphorylation occurs in the 
jejunum, duodenum or ileum of mice following low fructose doses (<0.5 g·kgBM-1). 
These findings therefore advance our fundamental understanding of mammalian 
fructose metabolism from an integrative perspective. 
 Orally ingested fructose is primarily converted into other substrates which 
circulate in plasma for oxidation by tissues (Tappy & Le, 2010). Major pathways of 
fructose metabolism include conversion to glucose and lactate. By sampling blood 
from the portal vein, Jang et al. (2018) demonstrate that low-dose fructose ingestion 
results in the majority of fructose appearing in the portal blood as glucose and lactate 
(~60%), with less than 20% appearing as fructose . This suggests that low fructose 
doses expose the liver to a similar metabolic milieu as does glucose ingestion. This 
then raises some important questions in relation to observations in humans, such as 
why fructose ingestion would therefore accelerate liver glycogen synthesis, stimulate 
hepatic de novo lipogenesis and exacerbate postprandial lipaemia (Tran et al., 2010; 
Fuchs et al., 2016; Gonzalez et al., 2016). 
 The answers to these questions may lie in the interaction between the fructose 
dose and relative organ sizes. As highlighted by Jang et al. (2018), the role of the 
small intestine in fructose metabolism may not be conserved across species. Humans 
are renowned for having a relatively small gut; thought to be an evolutionary 
adaptation to energy dense food, thereby allowing greater brain size. Indeed, relative 
to body mass, humans have a smaller intestinal surface area compared to rodents 
(Casteleyn et al., 2010). This may have consequences for the relative importance of 
the gut and the liver with respect to fructose metabolism. For example, in mice, the 
incremental dose of fructose from 0.5 to 1.0 g·kgBM-1 dramatically shifts whole-body 
fructose metabolism; the capacity of the small intestine is saturated, exposing the liver 
to more fructose. Under these conditions, the murine liver would be expected to exhibit 
alterations in glycogen and lipid metabolism had glucose only been ingested 
(Gonzalez et al., 2016; Jang et al., 2018). In contrast, the human small intestine and 
liver are relatively smaller, which may explain why fructose doses as low as ~0.1 
g·kgBM-1 can elicit detectable increases in circulating fructose concentrations (Moore 
et al., 2000) and 0.33 g·kgBM-1 is sufficient to stimulate de novo lipogenesis (Tran et 
al., 2010).  
The elegant dose-response data provided by Jang et al. (2018) indicate that at 
the above doses, none of the ingested fructose would appear in the portal blood as 
fructose in mice. Humans may therefore saturate the small intestine’s capacity for 
fructose metabolism at lower relative doses than mice. Supporting this, when doses 
are scaled to body surface area (more appropriate for comparing mice and human oral 
dosing) the saturation of intestinal fructose metabolism would occur at only ~5 g sugar 
intake (e.g. ¼ of a banana). Whilst data in humans are needed to support or refute 
this hypothesis, the saturation of intestinal fructose metabolism at low fructose doses 
may thereby make differences in small intestine metabolism redundant with typical 
sugar intakes, shifting the focus back to the liver. In humans, high-dose fructose-
glucose co-ingestion (1 to 3 g·kgBM-1) dramatically enhances liver glycogen synthesis 
compared to glucose only (Gonzalez et al., 2017). Unfortunately, there is no available 
evidence to infer the liver glycogen responses to lower fructose doses in humans. A 
better understanding of the ability to generalise the dose-response of fructose 
ingestion from mice to humans should therefore be a research priority. 
 Defining a dose of fructose whereby metabolism is affected in such a way that 
health is impaired is not easy. Even when considering only humans, there may be sex 
differences and/or effects dependent on absolute (g) versus relative (g·kgBM-1) 
quantities (Tran et al., 2010), and the metabolic consequences of fructose also depend 
upon whole-body energy status. High fructose diets may only negatively affect 
metabolism during positive energy balance and when relatively sedentary (Figure 1). 
In fact, only very modest amounts of exercise seem to be required to obliterate many 
effects of fructose overfeeding, independent of energy balance (Egli et al., 2013). 
Perhaps a high energy flux is why Tour de France cyclists display exquisite metabolic 
health even though it has been reported they consume up to 6.7 g·kgBM-1 sugar per 
day (Saris et al., 1989). 
 Whilst there is clearly further work needed understand the precise metabolic 
fate of fructose ingestion in humans, the work by Jang et al. provides an important 
step forward in our current understanding of mammalian fructose metabolism. The 
potential for intestine-liver interactions in human fructose metabolism should not be 
neglected, as this may provide important links between diet and disease. 
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 Figure 1. In mice, low doses of dietary fructose are primarily metabolized by the small 
intestine, exposing the liver primarily to glucose and lactate. High doses of fructose 
saturate the intestinal capacity to metabolize fructose, exposing the liver to higher 
fructose concentrations. Assuming this intestinal metabolism is conserved in humans, 
due to a relatively small gut it is unknown at what point intestinal fructose metabolism 
is saturated in humans. In humans, the metabolic fate of fructose depends not only on 
organ and body size, but also whole-body energy flux.
Low dose fructose
(≤0.5 g/kg)
High dose fructose
(>0.5 g/kg)
High dose fructose
(up to 3 g/kg/day)
Metabolically
Healthy
Hepatic insulin resistance?
De novo lipogenesis?
Hypertriglyceridemia?
Metabolically
Healthy
Metabolically
Healthy
Glucose
Lactate
Fructose
Glucose
Lactate
Fructose
Glucose?
Lactate?
Fructose?
Glucose?
Lactate?
Fructose?
Glucose?
Lactate?
Fructose?
Low dose fructose
(?? g/kg/d)
High dose fructose
(~3 g/kg/day)
+ve Energy Balance
? ??
Hepatic insulin resistance?
De novo lipogenesis?
Hypertriglyceridemia?
Selected Reading 
 
Casteleyn C, Rekecki A, Van der Aa A, Simoens P & Van den Broeck W. (2010). 
Surface area assessment of the murine intestinal tract as a prerequisite for 
oral dose translation from mouse to man. Lab Anim 44, 176-183. 
 
Egli L, Lecoultre V, Theytaz F, Campos V, Hodson L, Schneiter P, Mittendorfer B, 
Patterson BW, Fielding BA, Gerber PA, Giusti V, Berneis K & Tappy L. 
(2013). Exercise prevents fructose-induced hypertriglyceridemia in healthy 
young subjects. Diabetes 62, 2259-2265. 
 
Fuchs CJ, Gonzalez JT, Beelen M, Cermak NM, Smith FE, Thelwall PE, Taylor R, 
Trenell MI, Stevenson EJ & van Loon LJ. (2016). Sucrose ingestion after 
exhaustive exercise accelerates liver, but not muscle glycogen repletion when 
compared to glucose ingestion in trained athletes. J Appl Physiol 120, 1328-
1334. 
 
Gonzalez JT, Fuchs CJ, Betts JA & van Loon LJ. (2016). Liver glycogen metabolism 
during and after prolonged endurance-type exercise. Am J Physiol Endocrinol 
Metab 311, E543-553. 
 
Gonzalez JT, Fuchs CJ, Betts JA & van Loon LJ. (2017). Glucose Plus Fructose 
Ingestion for Post-Exercise Recovery-Greater than the Sum of Its Parts? 
Nutrients 9. 
 
Jang C, Hui S, Lu W, Cowan AJ, Morscher RJ, Lee GR, Liu W, Tesz GJ, Birnbaum 
MJ & Rabinowitz JD. (2018). The small intestine converts dietary fructose into 
glucose and organic acids. Cell metabolism 27, 351-361. 
 
Moore MC, Cherrington AD, Mann SL & Davis SN. (2000). Acute fructose 
administration decreases the glycemic response to an oral glucose tolerance 
test in normal adults. J Clin Endocrinol Metab 85, 4515-4519. 
 
Saris WH, van Erp-Baart MA, Brouns F, Westerterp KR & ten Hoor F. (1989). Study 
on food intake and energy expenditure during extreme sustained exercise: the 
Tour de France. International journal of sports medicine 10 Suppl 1, S26-31. 
 
Tappy L & Le KA. (2010). Metabolic effects of fructose and the worldwide increase in 
obesity. Physiol Rev 90, 23-46. 
 
Tran C, Jacot-Descombes D, Lecoultre V, Fielding BA, Carrel G, Le KA, Schneiter P, 
Bortolotti M, Frayn KN & Tappy L. (2010). Sex differences in lipid and glucose 
kinetics after ingestion of an acute oral fructose load. Br J Nutr 104, 1139-
1147. 
 
 
